Framework residue substituted humanized COL-1 antibodies and their use

Details for Australian Patent Application No. 2005322869 (hide)

Owner The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services

Inventors Schlom, Jeffrey; Padlan, Eduardo; Kashmiri, Syed

Agent Griffith Hack

Pub. Number AU-B-2005322869

PCT Pub. Number WO2006/074071

Priority 60/640,672 30.12.04 US

Filing date 30 December 2005

Wipo publication date 13 July 2006

Acceptance publication date 12 May 2011

International Classifications

C07K 16/30 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

A61P 35/00 (2006.01) Antineoplastic agents

C07K 16/46 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - Hybrid immunoglobulins

Event Publications

16 August 2007 PCT application entered the National Phase

  PCT publication WO2006/074071 Priority application(s): WO2006/074071

12 May 2011 Application Accepted

  Published as AU-B-2005322869

8 September 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005322870-Systems and methods for providing client-side acceleration techniques

2005322855-Pyrimidine derivatives as kinase modulators and method of use